FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

FDA Prodded to Improve Surrogate Endpoint Transparency

A Federation of American Scientists online paper says FDA, other federal research agencies, and Congress should take steps to increase surrogate endpo...

latest-news-card-1
Human Drugs

Taiho Reports Unfavorable DMD Drug Data

Taiho Pharmaceutical reports disappointing data from its Phase 3 extension study of TAS-205 (pizuglanstat) in patients with Duchenne muscular dystroph...

latest-news-card-1
FDA General

FDA Urged to Expand Real-World Data Use

A bioethicists opinion piece in The Hill says FDA needs to expand its reliance on real-world clinical data to monitor the safety and effectiveness of ...

latest-news-card-1
Human Drugs

Priority Review for Mercks Winrevair

FDA accepts and will give priority review to a Merck sBLA for a Winrevair labeling update based on ZENITH trial results.

Biologics

Vaccine Regulation Now a Political Process: Gottlieb

Former FDA commissioner Scott Gottlieb raises significant questions about the current administrations handling of vaccines and vaccine innovation in w...

latest-news-card-1
Human Drugs

Sandoz Recalls 1 Cefazolin Lot

FDA says Sandoz has recalled one lot of Cefazolin for injection following a customer complaint that vials of another drug were included in a Cefazolin...

Medical Devices

FDA Clears Philips SmartSpeed Precise Software

FDA clears Philips SmartSpeed Precise AI-enhanced software for MRI systems.

latest-news-card-1
Human Drugs

Myelodysplastic Syndrome Drug Development Guide

FDA publishes a draft guidance to assist sponsors in developing drugs to treat myelodysplastic syndromes.

latest-news-card-1
Biologics

Positive Phase 3 Results for Moderna Flu Vaccine

Moderna says its mRNA-1010 investigational seasonal flu vaccine achieved very positive results in a Phase 3 efficacy trial.

latest-news-card-1
Human Drugs

Bioresearch Monitoring Violations by Dr. Peter Michael

FDA warns Hialeah, FL-based physician Peter Michael about failing to follow the investigation plan in two clinical studies.